

Supplementary Figure 1. Dominant IgM B-cell clones are present in GBS patients

before and after treatment with IVIg. RNA was isolated from PBMC before and one week after treatment with IVIg and immunoglobulin transcripts were sequenced.

Potential clones were identified as the percentage of (all) *IGM* sequences having the same V and D region usage and the same CDR3 length. Within each patient, unique clones are represented by a different color (only clones of >1%). Before treatment, a dominant clone (>5%, indicated with asterisks) was identified in all patients (A). After treatment, the number of dominant clones did not increase. Analysis of the CDR3 amino acid composition of the most prevalent clone of every patient before and after treatment identified common motifs (data shown as frequency; B). Comparison of the IgM clone frequencies before and after treatment revealed overlap of several clones in patient 1 (C).

